Status:
UNKNOWN
Study of Innovative Drug Strategies in Improving Left Ventricular Function After Mitral Repair
Lead Sponsor:
China National Center for Cardiovascular Diseases
Collaborating Sponsors:
Shanghai Children's Medical Center
Chinese Academy of Medical Sciences, Fuwai Hospital
Conditions:
Congenital Mitral Insufficiency
Eligibility:
All Genders
Up to 14 years
Brief Summary
The goal of this observational study is to compare the safety and effectiveness of a modified drug therapy with traditional drug therapy in pediatric patients after mitral repair. The main questions ...
Eligibility Criteria
Inclusion
- under 14 years old
- after mitral valve repair
Exclusion
- Patients with heart failure requiring ventricular assist or cardiac synchronization therapy
- Patients with severe pulmonary hypertension (pulmonary arterial pressure \>6 Wood·U)
- Patients with severe liver and kidney failure
- Patients who are allergic to related medications
- Patients with symptomatic hypotension who cannot tolerate related drugs
Key Trial Info
Start Date :
April 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
164 Patients enrolled
Trial Details
Trial ID
NCT06039592
Start Date
April 1 2022
End Date
December 31 2024
Last Update
September 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fuwai hospital
Beijing, Beijing Municipality, China, 100037